Shaping AI 


with Topology

Investor Presentation — June 2021

Agenda
Presentation
1. L2F in a nutshell
2. Giotto Compliance
3. Growth Strategy for Giotto Compliance
4. Research
5. Financial Analysis
6. About L2F

2
1
L2F in a nutshell
Summary

Research Product Commercial Financing

Topological Giotto Compliance 9 Customers Currently raising CHF 4.8 Mio

Data Analysis
EUR 400k of ARR
EUR 1 Mio+ potential ARR
with current sales pipeline
CHF 3.2 Mio 

Series A round in 2019
CHF 1.6 Mio research grants

EUR 1 Mio+ potential ARR

with other departments of
current customers

3
1
L2F in a nutshell
SaaS product

Giotto Compliance

Giotto Compliance is an AI-based tool supporting medical device

companies to comply with the new EUMDR regulation. By facilitating
automated data extraction with human supervision, Giotto Compliance
speeds up the clinical evaluation and the post-market ongoing
obligations allowing very significant cost and time savings.

Large medtech companies Small and medium* medtech

based (or selling) in Europe: companies based (or selling) in
1 1
~1350 companies ​ Europe: ~25.500 companies

4 1. https://www.swiss-medtech.ch/sites/default/files/2020-08/MTE_EN_2018.pdf
1
L2F in a nutshell
Research

Topological Data Analysis

Our R&D department designs and develops new ML

algorithms based on topology. Those novel algorithms
aim at better understanding how models work, hence
improving robustness and interpretability of AI.​

5
1
L2F in a nutshell
The value of our technology​

Interpretability
Detailed understanding and
explanation of model behaviour
and performance.

Performance
Giotto-TDA
2
Powerful feature engineering
and visualisation techniques.

Robustness
Increased reliability on
unseen data.

6 2. https://github.com/giotto-ai/giotto-tda
Giotto
Compliance
2
Giotto Compliance
Medical Device Regulation

01
In May 2021, the new European
regulations on medical devices
(EUMDR) will take effect.
02
The most impactful changes
are on Clinical Evaluation and
Post Market Surveillance.

Before EUMDR After EUMDR

The focus was on how to obtain The focus is more on how to

03
Those changes strengthen the
requirements by adding greater
emphasis on providing
“sufficient clinical evidence”.
04
Thus, creating a massive need
for tools capable of
automating the systematic
literature review process,
from searching, screening, data
extraction to appraisal.
the approval of medical devices
Post market surveillance
requirements were basic
retain the approval throughout a
medical device’s lifecycle
Increased post market
surveillance requirements were
added

8
2
Giotto Compliance
How does Giotto Compliance fit into the systematic review process?

9
2
Giotto Compliance
Value

Automation
Through the use of state-of-the-art and custom Natural
Language Processing technologies, Giotto unlocks the
power of automation for screening, extraction and analysis of
records. This enables users to save time and focus their
expertise on other critical tasks.

Digitalisation
Giotto offers a user-friendly interface to produce, centralise
and update documents, plans and reports following the
latest standards for compliance processes. Notified
bodies will directly access and review applications through
Giotto Compliance interface.

10
2
Giotto Compliance
How much can you save using Giotto Compliance?
1/2

Average number of hours spent on the preparation of a CER:

% of the CER preparation associated with the literature search and review:

% of time-saving during the systematic review process using Giotto Compliance:

150 Hours

40%

50%

Medical writer’s average hour rate: 150€

Giotto Compliance saves 30hours per CER

Giotto Compliance saves 4.500€ per CER

11
2
Giotto Compliance
How much can you save using Giotto Compliance?
2/2

Return on Investment 

In a scenario of performing 

#30 CERs per year for class III devices

Giotto Compliance subscription would cost you ~30K/year

You would save ~100K/year
ROI = 350%

12
2
Giotto Compliance
Past milestones

S1 2019

Open source release

of giotto-tda
S1 2020
Technology checkpoint 2
Development of data
extraction models specific
to medical publications
2 TDA-enhanced word
embedding techniques
3 TDA-enhanced general
S1 2021

Deep Learning frameworks

First NLP software in Technology checkpoint 1 First release of Giotto

production Compliance
Graph-based concept
Raw technology for data clustering AI-based data extraction
extraction, unsupervised
S2 2019 2 Topological models for S2 2020 2 Human-in-the-loop
screening, and extractive screening
summarization validation
2 Deployment to production 3 Flexible tagging interface
in the context of an with smart navigation tool
industrial collaboration 4 Finetuning options
5 Documentation query
13
2
Giotto Compliance
Product roadmap

Second release

S1 2021
Support for analysis and
enhanced team features
Self-customization for
new customers
2 Automated data analysis
and report generation
3 Collaborative team
S1 2022
Support for the entire
EUMDR compliance process
Direct access to Notified
Bodies for review

features

Support for Protocol, Support for other PMS

Screening & Appraisal obligations
Connection with relevant Automatic review of
databases S2 2021 benefit-risk determination S2 2022
2 Screening based on 2 Background automatic
abstract review vigilance processes
3 Appraisal tagging based on 3 Tracking of PMS
standardized frameworks activities

14
2
Giotto Compliance
Subscription Model

Based on the number of projects opened in Giotto Compliance


(usually 1 project corresponds to 1 CER)

Underlying device class Yearly subscription per project

Class I 400€/Year

Class II 750€/Year

Class III 1000€/Year

Unlimited users

15
2
Giotto Compliance
Market analysis – EUMDR compliance
1/2

"Postmarket surveillance needs to be brought into a continuous
evaluation and improvement cycle that links to continuous reviews of
risk management information, as well as to a regular update of a public
summary of clinical evaluations, safety, and performance. The new
regulations require plans for postmarket surveillance, reports, safety
update reports, systems for management of serious incidents and, trend
reports."​
"AI’s ability to process large volumes of data with speed and
accuracy can potentially transform regulatory compliance.
Eventually, the continued use of AI in regulatory compliance
can eliminate the need for humans in the process altogether. "
Forbes – Why regulatory compliance can be complicated and how AI can simplify it​

MedDeviceOnline – Key changes to understand the new European MDR and IVDR

16
2
Giotto Compliance
Market analysis – EUMDR compliance
2/2

European Medtech Industry:​

110 Billion € market​

The market for NLP in healthcare is

projected to grow at a 5y CAGR of 20.5%

Focus on the EUMDR

“Recent incidents, including the breast implant crisis and the hip replacements, have
now prompted urgent regulatory and compliance reforms to the industry. Among the
27K companies in Europe​

most significant of these are the European Commission’s 2012 proposals for
regulation on medical devices (EU MDR) and in-vitro diagnostics (EU IVDR). With the
95% SMEs​ formal publication of guidance imminent, the proposals will give national regulators
much more control and oversight of the medical devices industry — with adoption
mandatory. If companies do not comply with these upcoming changes then this
could possibly result in a company losing its license to operate. The impact of this
regulation can dramatically alter the operations of medical device manufacturers and
even impact the composition of their existing as well as future portfolios.”

Medtech Europe – the european medical technology industry Deloitte – Preparing for the future: The New European Union medical devices regulation

17
2
Giotto Compliance
Current potential revenue of Giotto Compliance​

EUMDR
There are 500K types of medical devices on the EU Market *​

Those medical devices need to comply with the EUMDR​

EUMDR compliance requires regular updates of the Clinical Evaluation Reports (CER)

500K CERs to be updated regularly​

Average of 700€ per CER/year​

350M€ potential ARR​

18 * Source: European Commission​

2
Giotto Compliance
Future potential revenue of Giotto Compliance

EUMDR version​ FDA version​ CFDA version​

Potential ARR: 350M€​ Potential ARR x 2​ Potential ARR x 3​

Today 2023 2024

19
2
Giotto Compliance
Competition
1/4

Basic

Digitalisation [RobotAnalyst]
[Sysrev]
Advanced

Automation

[Raxter]
[DistillerSR]
[Covidence]
Giotto Compliance

[GradePro]

Advanced

Digitalisation

[JBI Summari]
[Syrf]

[Swift-Review]
[RevMan]
[RobotReviewer]
[Rayyan]
[Mendeley Reference [Systematic Review
Management] Data Repository]
Basic

20 Automation
2
Giotto Compliance
Competition
2/4
No

2
3
1
Company

Giotto Compliance
Covidence
GRADEpro
Raxter
Data
Screening
Data
Extraction
Report
Generation
EUMDR
Specific
Digital Review
Submission (Nobo's)
Soon (2023)

4 DistillerSR
5 JBI SUMARI
6 SysRev
7 Syrf
8 Rayyan QCRI
9 Review Manager (RevMan)
10 SWIFT-Review
11 RobotReviewer
12 RobotAnalyst
13 Mendeley Reference Management
14 Systematic Review Data Repository+
2
Giotto Compliance
Competition - Substitutes
3/4

No

1
Main Competitors

Castor
Reason

End-to-end data solution for device and diagnostics trials (MDR generalist tool):
Captures, processes, and integrates data from multiple sources (FIH, Pivotal and
Post-Marketing studies, supporting compliance with MDR, IVDR, CE mark, and FDA De
Novo submissions) on a compliant electronic data capture (EDC) for clinical trials).

2 Celegence Provides a regulatory intelligence platform to support companies with knowledge

management, interpretation of local and regional regulations / Team write the
highest quality Clinical Evaluation Reports, faster / (Partner Option).

3 Kalypso Help companies achieve EU MDR compliance and drive innovation with digitally-enabled
products, processes and business models.

4 Clever Compliance Nordic state-of-the-art compliance software solution: Compliance reports, monitoring
regulatory changes, compliance documentation repositery, supplier compliant interface,
project collaboration, product compliance workflow.

5 Veeva Veeva MedTech Suite improves speed and agility throughout the device and diagnostic
lifecycle: faster time to market, stronger compliance throughout the product lifecycle, e cient
ffi

creation and dissemination of clinical data.

22
2
Giotto Compliance
Competition - Substitutes
4/4

No

7
Main Competitors

KeborMed

Mantra Systems
Reason

Connect, collect, present and manage data from multiple sources, integrate, and provide
clinicians with valuable insights into their patients' evolution, both historically and in real
time.

Build clinical evidence generation systems and perform data analysis services, enabling
clients to meet MDR requirements for Clinical Evaluation, PMS, PMCF and Vigilance.

8 Leitwert Swiss Firm / Data generated by medical wearables holds huge potential to improve
healthcare and clinical research / Provide market leading firmware for wearable devices,
enable device manufacturers to efficiently manage their device fleet and practitioners to
integrate wearables in clinical processes and Digital Health solutions.

9 Medisante Swiss Firm / Integration of Patient-Generated Health Data (PGHD) into clinical systems.

10 Aligned Swiss Firm / Built for MD regulatory compliance / Cut time spent on documentation, Free up
valuable staff for innovation, Stay compliant with regulations.

23
2
Giotto Compliance
Key facts

9 Customers

EUR 400k of ARR

EUR 1 Mio+ potential ARR with current sales pipeline

EUR 1 Mio+ potential ARR with other departments of current customers

24
Growth Strategy
for Giotto
Compliance
3
Growth Strategy
Repeatble process to convert leads into paying customers

SDR team

Outbound leads Sa
les
Q
Le ualifi
ad ed

ting d
Bye bye

not qualified

AE team

Demo Customer stage I

Configuration
Customer stage II

Subscription

MDR team a rke d Lea

M lifie
a AE CSM team
Qu
Inbound leads
/

AE team Customer Success

Stand by
Follow-up, training, content, upsell
qualified but…

Wrong timing

Need approval

Need extra demo

MDR team
Nurturning list

26 marketing
3
Growth Strategy
Outbound strategy

SDR team

01
Repeatable process to target potential customers

Persona-based prospecting ​

(Buyer personas)​
Account-based search

(Ideal company profile > Buyer personas)

02 Transform LinkedIn prospects into lists of email targets

0.20$ per valid email

03 Enroll target contacts into automated email sequences​

Sequence = 1st cold email + 4 follow-up emails ​

04 Demo

27
3
Growth Strategy
Inbound strategy​ Effective fishing net capable of attracting potential customers

Social Media Posts​

Engage with specific targets​

Reputation and awareness​

Sporadic lead generation​

Landing Page​
Reputation, trust​

Get Demo Requests​ Videos

Giotto Compliance teaser​

Giotto Compliance use cases​

Feed social media, landing page, newsletter​

Events Demo Blog Articles​

Awareness, reputation Boost SEO -> future organic search results​

Attending and/or Sponsoring Feed social media, landing page, newsletter​

Perform Demos Sporadic lead generation​

Newsletter/Webinar​ Ad Campaigns​
Share relevant content with leads and customers​
Google Search and Display (EUMDR)​

Reputation and awareness​

Feed landing page​

Sporadic lead generation​ Get Demo Requests

28
3
Growth Strategy
Timeline

Giotto Compliance​
Launch​

Start outbound​
Inbound testing​
Investment
round A2

Speed up outbound​
Start inbound​
Investment
round B​

Massify outbound​
Massify inbound​

February May April


2021 2021 2022

29
Research
4
Research
Topological Data Analysis 101​

Main features:​
Solid mathematical foundations
Based on combinatorial algebraic topology​
Persistent homology: ​
Tool to extract geometric information of the
shape of point clouds in a non-parametric way
Mapper algorithm: ​
Visualization of high dimensional data that
preserves features related to shape
Invariant under continuous deformations​
Provably stable against noise

a) Original Point Cloud b) Coloring by filter value c) Binning by filter value d) Clustering and network construction

31
4
Research
Added value of topology in machine learning​
1/3

Stability against
noise
Enhance the generalisation and
predictive power of general ML
algorithms

Early warning signal of future crash Nominal regime

3
The above is an example of the predictive power of topology in financial time series. 

32 3. https://towardsdatascience.com/detecting-stock-market-crashes-with-topological-data-analysis-7d5dd98abe42
4
Research
Added value of topology in machine learning​
2/3

Invariance under
deformation

x
Simplify and transform models to
increase robustness

x
Topological
regularisation​

y
y

Regularized models work

better in production​

33
4
Research
Added value of topology in machine learning​
3/3

Graph repsentation, no alteration of the

high dimensional shape of the point cloud
unlike standard ML tools such as PCA
High dimensional
data visualisation

! Complete removal of the inner void!

34
4Research
Some relevant applications of TDA algorithms​

Topological approach to identify alterations of brain

Topology for protein expression analysis with relevant
consequences in pharmacology and precision
medicine.​The sensitivity of topology in analyzing high
dimensional datasets is a major added value.

vascularization to prevent development of diseases

-TDA
like stroke. Strong correlation between the shape of
brain arteries and the age of the patient.

Topological data analysis is used to get new insights into

the word embedding space to improve the
performances of search engines. An original and novel
example in the field can be found here.
35
4
Research
How TDA enhances NLP model performance​

The engines behind Giotto-compliance are based on NLP.​

T​ he following tasks are crucial in Giotto-compliance:

1. Understanding the topic of a sentence​ 3. Querying documents​
2. Text summarization​ 4 . Ranking documents

All those tasks depend on word embedding (WE) techniques.

Current NLP models based on WE fail at capturing all the semantics.​ A graphical representation of a word embedding space using Mapper​

We use our prorietary WE technique based on topology. ​

36
4
Research
Proprietary open-source libraries​

Giotto-deep
A Python library creating interpretable and
topologically enhanced deep learning
algorithms. Fully compatible with Pytorch
and transfer learning models.
Giotto-tda
The most downloaded library on topological
data analysis. ​
It contains brand new high-performance
Giotto-time
A Python library for multi time series
analysis, with innovative algorithms to
perform forecasting, correlation analysis,
algorithms, powerful visualization tools for detrending, denoising and error estimates.​
high dimensional data, and an easy interface.

AGPL 3.0
150k
500+

License Downloads Stars

37 5. github.com/giotto-ai​
Financial
Analysis
5
Financial Analysis
Timeline

2019

Series A2

Giotto Compliance
2022

Series C

Series A Series B
Giotto TDA

2021 2024

39
5
Financial Analysis
Past milestones

04.2018

Junior debt: CHF

320K – Private
investors
11.2018

Capital increase:
CHF 3.2M Series
A – 4FO Ventures
10.2019
Grant: CHF 960K –
Innosuisse:
Topological suite
for deep learning

Seed loan: CHF Grant: CHF 550K Growth loan: CHF

100K – Fondation – Innosuisse: 500K - Fondation
pour l’Innovation Topological early pour l’Innovation
07.2018 08.2019 11.2019
Technologique warning signals Technologique

40
5
Financial Analysis
P&L
1/2

Revenues and direct cost

of revenues
Giotto Compliance
Other revenues
2020 (A)

186'350
-
Profit and loss account 2020-2025

2021

52'958
354'000
2022

1'074'266
354'000
2023

5'134'946
354'000
2024

13'972'698
354'000
2025

29'545'970
354'000
Total revenues 186'350 406'958 1'428'266 5'488'946 14'326'698 29'949'970
Giotto direct costs of revenues 10'117 37'696 139'827 545'895 1'476'837 3'412'541
Gross Profit 176'233 369'262 1'288'439 4'943'051 12'849'861 26'537'429

41
5
Financial Analysis
P&L
2/2

Operating expenses

Research and development

Sales and marketing
2020 (A)

599'996
368'172
Profit and loss account 2020-2025

2021

859'946
324'266
2022

1'555'598
1'077'474
2023

2'852'546
2'681'480
2024

3'276'077
2'752'390
2025

3'426'919
2'836'237
General and administration 465'685 393'714 508'498 743'384 966'637 1'009'874
EBITDA (1'257'620) (1'208'764) (1'853'131) (1'334'359) 5'824'758 19'264'399
Depreciation and amortization 10'000 395'280 766'560 766'560 766'560 402'113
Financing impacts 29'619 35'000 35'000 35'004 33'587 9'000
Net income before taxation (1'297'239) (1'639'044) (2'654'691) (2'135'923) 5'024'611 18'853'286
Taxation @ 13.8% - - - (22'387) (693'396) (2'601'754)
Less: tax losses carried forward utulized - - - 22'387 693'396 1'819'176
Net income after taxation (1'297'239) (1'639'044) (2'654'691) (2'135'923) 5'024'611 18'070'709

42
5
Financial Analysis
Cash flow statement 2020-2025
Cash flow
2020 (A) 2021 2022 2023 2024 2025

Net profit (1'297'239) (1'639'044) (2'654'691) (2'135'923) 5'024'611 18'070'709

Depreciation and amortization - tangible assets 10'000 24'000 24'000 24'000 24'000 24'000

Research and development costs capitalized (857'930) (359'964) 0 0 0 0

Amortization - intangble assets 0 371'280 742'560 742'560 742'560 378'113

Cash generated-operations -2'145'169 -1'603'728 -1'888'131 -1'369'363 5'791'171 18'472'822

(Increase)/decrease in debtors 21'538 (80'000) (65'000) (60'000) (75'000) (35'000)

Increase/(decrease) in creditors (169'042) (265'000) 20'000 80'000 105'000 100'000

Working capital movements -147'504 -345'000 -45'000 20'000 30'000 65'000

Operating cash flow (2'292'673) (1'948'728) (1'933'131) (1'349'363) 5'821'171 18'537'822

Investments in fixed assets (5'000) (5'000) (40'000) (60'000) (93'685) (93'685)

Loans 1'919'000 - (70'000) - (300'000) (869'000)

Capital paid in - 3'300'000 5'000'000 - - -

Total financing impacts 1'919'000 3'300'000 4'930'000 0 (300'000) (869'000)

Net increase/decrease in cash (378'673) 1'346'272 2'956'869 (1'409'363) 5'427'486 17'575'137

Cash balance brought forward 827'213 448'540 1'794'812 4'751'681 3'342'317 8'769'803

Cash
41 balance carried forward 448'540 1'794'812 4'751'681 3'342'317 8'769'803 26'344'940
5
Financial Analysis
Balance sheet
1/2
Assets

Cash and Short Term Investments

Accounts Receivable
Other receivables
31.12.2019

827'213
0
46'538
Balance sheet 2019-2025

31.12.2020

448'540
10'000
15'000
31.12.2021

1'794'812
50'000
55'000
31.12.2022

4'751'681
70'000
100'000
31.12.2023

3'342'317
100'000
130'000
31.12.2024

8'769'803
160'000
145'000
31.12.2025

26'344'940
180'000
160'000
Total current assets 873'750 473'540 1'899'812 4'921'681 3'572'317 9'074'803 26'684'940
Tangible fixed assets 68'733 63'733 44'733 60'733 96'733 166'418 256'418
Financal fixed assets 10'001 10'001 10'001 10'001 10'001 10'001 10'001
Intagible fixed assets 1'059'494 1'917'424 2'626'108 1'883'548 1'140'988 398'428 0
Total fixed assets 1'138'227 1'991'157 2'680'842 1'954'282 1'247'722 574'847 266'419
Total assets 2'011'978 2'464'697 4'580'653 6'875'962 4'820'039 9'649'650 26'951'358

44
5
Financial Analysis
Balance sheet
2/2
Liabilities and Equity

Trade Accounts payable

Other Accounts payable
Accrued expenses
Total short term liabilities
31.12.2019

59'460
263'894
105'688
429'042
Balance sheet 2019-2025

31.12.2020

115'000
1'350'000
145'000
1'610'000
31.12.2021

130'000
130'000
235'000
495'000
31.12.2022

135'000
130'000
250'000
515'000
31.12.2023

160'000
155'000
280'000
595'000
31.12.2024

210'000
190'000
300'000
700'000
All figures in CHF

31.12.2025

250'000
210'000
340'000
800'000
Loans 600'000 1'169'000 1'239'000 1'169'000 1'169'000 869'000 0
Total long term liabilities 600'000 1'169'000 1'239'000 1'169'000 1'169'000 869'000 0
Share premium 3'115'806 3'115'806 6'595'150 11'565'641 11'565'641 11'565'641 11'565'641
Retained earings -717'673 -2'278'502 -3'575'741 -5'214'785 -7'869'476 -10'005'399 -4'980'788
Result current year -1'560'829 -1'297'239 -1'639'044 -2'654'691 -2'135'923 5'024'611 18'070'709
Share capital 145'632 145'632 166'288 195'797 195'797 195'797 195'797
Total share holders’ equity 982'936 -314'303 1'546'653 3'891'962 1'756'039 6'780'650 24'851'359
Total liabilities and equity 2'011'978 2'464'697 3'280'653 5'575'962 3'520'039 8'349'650 25'651'359

45
5
Financial Analysis
Capital increases - Use of proceeds

Research activities

Compliance product development

CHF 4.8 MILLION SERIES A2

June 2021

1'300

1'500
Figures in CHF ‘000s

CHF 5 MILLION SERIES B


April 2022

1'000

1'500

Compliance growth activities 1'500 1'500

General and administration overheads 500 500

Working capital 0 500

TOTAL 4’800 5’000

46
5
Financial Analysis
Headcount summary

Research
Department

Management + IT security
Giotto Compliance development

Total research and development headcount

Headcount summary 2019-2025

12.2020

6
6
12
1
12.2021

2
10
3
15
12.2022

2
13
8
23
12.2023

2
19
14
35
12.2024

2
19
14
35
12.2025

3
19
14
36
Growth Compliance 2 7 27 27 27 31
Total sales and marketing headcount 2 7 27 27 27 31
Finance headcount Switzerland (CFO = 40%, Accountant = 40%) 1 1 1 1 2 2
Administration headcount Switzerland 1 1 2 3 3 3
Total finance and administration headcount 2 2 3 4 5 5
Total company headcount (including Interns and Contractors) 16 24 53 66 67 72

47
5
Financial Analysis
Exit strategy

Acquisition by another
currently larger machine
learning platform
Horizon 2022
or later
Very profitable business with potential
to expand into other related areas
such as healthcare AI solutions - remain
standalone, with existing shareholders
selling out to other shareholders or new
investors if desired

Proven track record with

compliance product allows
trade sale to a major Medical
Device solutions provider

Horizon 2021
 Horizon 2023

or later or later

48
About L2F
6
About L2F
Management L2F’s management reflects expertise in both
Business and Research & Development

Aldo Podestà
Christopher Bolton
Matteo Caorsi
André Dias

Chief Executive Officer & Director Chief Financial Officer Chief Scientist Head of Growth

Experience:
PMI Global Sales Strategy
Experience: Experience: Experience:
Startup manager
Chartered Accountant FCA Chief Extensive research background Chief Commercial Officer
Financial Officer (25+ yrs)

50
6
About L2F
Board L2F’s board is composed of experienced decision makers
boasting significant expertise and network in key areas

Nelly Chatue-Diop
Christophe Ganz
M atthieu Berger
Philippe Gillet

Chair Board Member Board Member Board Member

MSc Computer Science BSC Economics & CFA PhD Earth Science
Bachelor of Law
MBA Finance & Strategy (Chartered Financial Analyst) /Geophysics

Experience: Experience: Experience: Experience:

Consultant, Director, Board VP, General Manager, Chair, Financial Analyst, 
 Professor, Director, Board
Member, Chief Data Officer Director, Consultant Chief Investment Officer President, Chief Science Officer

51
6
About L2F
Why invest amid the global crisis?

Fully remote company & Cost efficient for enterprise

Cloud Product Focus on healthcare
quality team customers

52
Thank you

for your attention

Contact us
Aldo Podestà, CEO
 Christopher Bolton, CFO 

a.podesta@l2f.ch c.bolton@l2f.ch